Who is behind ClickDose
ClickDose is built by Tue Topholm, a software engineer and founder of Gaijin. Tue is not a medical doctor or pharmacist — he is a patient and family member who built the tool after seeing first-hand how hard it is to count clicks accurately by ear on a GLP-1 injection pen.
ClickDose began as an open-source side project to help others using Wegovy, Ozempic, or Mounjaro — especially people splitting doses to make an expensive pen last longer, or titrating slowly to reduce nausea and other side effects. Today it is available in twelve languages, so people can count their clicks and read the supporting information in their own language wherever these medications are sold.
Why ClickDose exists
GLP-1 medications are expensive and, in many countries, in short supply. To cope, many people dose-split or titrate in small steps — but the prefilled pens are designed for a handful of fixed doses, not the amounts in between. On most pens, each "click" you hear while dialling corresponds to a fixed, known increment of medicine. If you can count those clicks reliably, you can dial a precise partial dose. Counting them by ear is surprisingly error-prone — which is exactly the problem ClickDose was built to solve.
How it works — and your privacy
ClickDose listens through your device's microphone, detects each pen click, and converts the count into a dose for your specific pen. The detection runs entirely on your device: your microphone audio and your dose calculations are never uploaded, shared, or stored on a server. ClickDose installs as a Progressive Web App and works offline. The site uses privacy-friendly, cookie-less analytics for aggregate page views only — it does not profile individuals or sell data.
Independence and funding
ClickDose is free, carries no ads, and is not affiliated with, endorsed by, or funded by Novo Nordisk (Wegovy, Ozempic) or Eli Lilly (Mounjaro), or any other manufacturer. The source code is open and publicly auditable on GitHub. There are no sponsorships or commercial relationships that could influence the health information published here.
Our editorial process
Health content on ClickDose follows these principles:
- Every clinical claim is backed by a primary source — FDA prescribing information, EMA Summary of Product Characteristics (SmPC), or peer-reviewed studies. Sources appear at the bottom of each article.
- Figures and statistics are quoted directly from the manufacturers' official documents (Novo Nordisk for Wegovy/Ozempic, Eli Lilly for Mounjaro).
- Articles are updated when new label revisions are published, or when readers report errors.
- ClickDose is not a medical device. All content is informational — always verify your dose visually on the pen and talk to your doctor.
Seeking medical reviewer
We are actively looking for a pharmacist or physician to review content before publication. If you are a relevant professional interested in collaborating (credited with name and title), please email tt@gaijin.dk.
Contact
Questions, factual corrections, or suggestions: tt@gaijin.dk.
Source code and bug reports: github.com/ttopholm/click-counter.